• Poor medication adherence is common in diabetes potentially causing poor health outcomes and complications.
• Poor medication adherence is common in diabetes potentially causing poor health outcomes and complications.
• Complications caused by diabetes lead to increased health care costs.
• Recent meta-analysis of three observational retrospective studies (4804 type 2 diabetic patients) from the US showed that in a real-world setting, the average persistence to insulin analogue treatment was 65% during the 1-year follow-up (Wei W et al., 2014 ).
• Higher persistence was associated with older age, initiation with insulin glargine and baseline sitagliptin or exenatide use, lower HbA1c and lower health care utilisation.
• In Finland, the use of basal insulin is common (appr. 20% of type 2 diabetic patients) and supported by treatment guidelines.
• The majority of type 2 diabetic patients on basal insulin use insulin analogues (insulin glargine or insulin detemir) as their treatment.
• The epidemiological study by Valle et al. conducted in 2009 Valle et al. conducted in -2010 showed that only 22% of type 1 diabetic patients and 27% of insulin-treated type 2 diabetic patients are in good glycemic control (HbA1c <7.5% in T1DM, <7.0% in T2DM) in Finland highlighting the unmet needs of current basal insulins.
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Data and methods
Objective
There are currently no data on insulin treatment persistence in Finland and therefore the aim of this study was to analyse the discontinuation rate of initiated basal insulin analogue in type 1 (T1DM) and type 2 (T2DM) diabetic patients in Finland.
Data
The data was obtained from the national reimbursement registry. Study population consisted of diabetic patients who started basal insulin analogues (insulin glargine or insulin detemir) in 2012 having no insulin purchases in the registry before initiation.
Patients were followed by their insulin purchases for 18 months after the initiation and discontinuation of their initiated insulin was determined as with no purchase over 6 months period (Table 1) 
Methods
The diabetic status was determined from the coding based on the first reimbursement statement written by the physician. Due to coding system changes in the past, 16% of the patient did not have their diabetes type defined. The registry included also the data about age and gender of the diabetic patients and potential death during the study period. In addition, the data on initiation of other basal insulin analogue or GLP-1 receptor agonist in type 2 diabetic patients after the discontinuation was analysed to show potential treatment switches. 
Results
The data from 14 462 diabetic patients (18% had type 1 diabetes) was obtained from the reimbursement registry. The characteristics of the patients and type of diabetes are shown in 
Figure 1. Diabetic status of the patients initiating basal insulin treatment and discontinuing their initiated basal insulin treatment with insulin glargine (upper panels) and insulin detemir (lower panels).
• Overall 47 % of patients starting insulin detemir and 39 % starting insulin glargine patients discontinued their basal insulin treatment within 18 months after the initiation.
• Most of the patients stopped treatment within first 6 months after the initiation.
• In T1DM patients, 42 % of insulin glargine patients and 57 % of insulin detemir patients stopped the initiated treatment.
• In T2DM patients, 35 % of insulin glargine and 38 % of insulin detemir patients stopped the initiated treatment (Figure 2) • In only 15% of the patients discontinuing the initiated basal insulin, death or switch to other insulin or GLP1RA explained the discontinuation suggesting nonadherence to insulin therapy from other reasons.
• Type of insulin (OR 0.15), gender (OR 0.45), age (OR 1.82) and type of diabetes (OR 2.07) had statistically significant influence on patients' treatment adherence (p < 0.001 for all, VIF values 1.96-4.09, 1/VIF over 0.1).
Figure 2. Potential causes of discontinuation of initiated basal insulin in T2DM.
Insulin glargine T2DM (N=5222) Insulin detemir T2DM (N=2899)
Conclusion
There is a considerable proportion of diabetic patients discontinuing their initiated basal insulin analogue therapy. Future studies are warranted to examine the detailed reasons for discontinuation.
